The Pharma Playbook

intermediate7 min read

A regulatory business in a lab coat: US price erosion, ANDA pipelines and USFDA letters move these stocks more than quarterly sales.

Indian pharma is really several businesses stapled together: branded domestic formulations (steady, FMCG-like), US generics (volatile, price-war-prone), APIs/CDMO (manufacturing for others), and for a few, novel R&D. The stock reacts less to revenue than to regulatory events — an inspection letter can move 15% in a day.

Segment mix — domestic branded (stable, 10-12% industry growth) vs US generics (bigger but brutal): know which engine drives your company.
US price erosion — generic prices fall mid-single-digits to double-digits yearly as competitors pile in; guidance on erosion IS the US outlook.
ANDA pipeline — filed and approved US generic applications: the shelf of future launches; complex/limited-competition filings are worth many plain ones.
USFDA status — plant classifications (VAI acceptable; OAI/Warning Letter = new approvals frozen from that plant): the single biggest event risk.
R&D as % of sales — 6-10% typical; where in the value chain the company is trying to climb.

The market’s pharma mood swings on US genericisation math: a blockbuster drug going off-patent is a gold rush where the FIRST filer gets 180 days of exclusivity (fat margins), after which prices collapse 80-95%. So a company’s worth is not its current US sales but the quality of its pipeline — limited-competition molecules, injectables, complex generics — where price erosion is structurally slower. Plain oral-solid generics are a treadmill: you must launch constantly just to offset erosion on the existing book.

ExampleA midcap reports flat quarterly revenue — and rallies 12%. Buried in the release: its key plant cleared a USFDA re-inspection (OAI lifted), unfreezing 14 pending ANDAs including two limited-competition injectables. The quarter was history; the approval shelf just became monetisable. Pharma trades on the pipeline calendar, not the P&L calendar.

Test yourselfTwo generics firms have equal US revenue. A: 40 pending plain oral-solid ANDAs. B: 12 pending, mostly complex injectables. Which pipeline is worth more?

Usually B. Plain oral-solids face many competitors and rapid price erosion; complex injectables have fewer approved rivals, slower erosion, and better margins. Pipeline QUALITY (competition intensity per molecule) beats pipeline count.

✓ You learnedRead pharma by engine (domestic vs US vs API/CDMO), track US price-erosion guidance, weigh ANDA pipelines by competition-quality not count, and treat USFDA plant status as the event risk it is. The domestic franchise pays the bills; the US pipeline and the FDA decide the stock’s big moves.

FAQs

What exactly happens on a USFDA Warning Letter?

New approvals from that facility freeze until the FDA re-inspects and clears it — often 1-3 years. Existing products usually keep selling, so revenue holds while the FUTURE (pending launches from that plant) is what gets impaired. That asymmetry is why the stock reaction often looks outsized versus the current P&L impact.